Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Ociperlimab with GP in Advanced BTC
NCT05023109Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Feb 2021
- Primary completion
- Jan 2023
- Modality
- IgG Antibodies, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, ociperlimab in biliary tract carcinoma (BTC), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
tislelizumabociperlimab
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT05023109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023109.